We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 852

Sandoz v Amgen: An update
  • Bristows
  • USA
  • January 9 2018

In our most recent publication, the Bristows' Biotech Review (Page 3), we reported on the US Supreme Court decision which, at the time, was the latest

Standing Questioned Before the Federal Circuit in Momenta Pharms. v. Bristol-Myers Squibb Co.
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • January 5 2018

On December 5, 2017, the Federal Circuit held oral argument in Momenta Pharmaceuticals, Inc. v. Bristol-Myers Squibb Company, 17-1694. The case comes

Totality of Evidence Must Be Considered in Assessing Obviousness
  • McDermott Will & Emery
  • USA
  • December 29 2017

The US Court of Appeals for the Federal Circuit reversed a finding of non-obviousness, concluding that the district court clearly erred in relying on

Federal Biosimilars Act Preempts State Law
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • December 14 2017

On December 14, 2017, the Federal Circuit issued an opinion in Amgen v. Sandoz, holding that the Biologics Price Competition and Innovation Act of

Federal Circuit Affirms Apotex Bench Trial Win in Neulasta Biosimilar Suit
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • November 21 2017

On November 13, The Federal Circuit issued a decision affirming a district court judgment that Apotex did not infringe Amgen’s recombinant protein

Federal Circuit Patent Updates - November 2017
  • Wilmer Cutler Pickering Hale and Dorr LLP
  • USA
  • November 8 2017

Moore, J. Reversing finding of nonobviousness and holding claims invalid as obvious. “The district court clearly erred in finding a skilled artisan

Humira’s Wall of Patents Continues to Come Under Attack
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • November 6 2017

Sandoz’s most recent IPR filing fits nicely into a pattern of Humira patent challenges by the corporation, who, since July, has initiated post-grant

U.S. - What does the Impression Products v. Lexmark decision mean for drug companies? 5 takeaways
  • Hogan Lovells
  • USA
  • September 11 2017

Last May, the U.S. Supreme Court issued a highly-anticipated decision in Impression Products, Inc. v. Lexmark Int’l, Inc., reversing the Federal

At The Bench: 2017 Mid-Year Case Review
  • Harness, Dickey & Pierce, PLC
  • USA
  • September 7 2017

The Supreme Court held that all patent rights are exhausted upon the first sale of a Patented product, regardless of where the sale is made or whether

USA Court of Appeals for the Federal Circuit Decision Concerning on sale bar in Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc.
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • August 31 2017

The Court of Appeals for the Federal Circuit recently clarified in Helsinn Healthcare S.A. V. Teva Pharms. USA, Inc. elements required for a sale to